Market Overview

UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus Therapeutics

Share:
Related FOLD
Mid-Afternoon Market Update: U.S. Stocks Turn Positive; American Woodmark Shares Fall On Earnings Miss
Amicus Therapeutics Gets European Commission Approval For Galafold in Patients With Fabry Disease

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Amicus Therapeutics (NASDAQ: FOLD), and slightly raised its price target from $10.00 to $11.00.

Canaccord noted, “We think Q3 pivotal migalastat Fabry monoTx '011 trial data will be a strong positive catalyst and that the trial has a high chance of success. We also expect positive full Ph2 AT2220/ERT Pompe combo data in Q3/12. Our $11 target is based on a pNPV analysis.”

Amicus Therapeutics closed on Tuesday at $6.02.

Latest Ratings for FOLD

DateFirmActionFromTo
May 2016Bank of AmericaInitiates Coverage onBuy
Apr 2016BairdInitiates Coverage onNeutral
Mar 2016Goldman SachsInitiates Coverage onNeutral

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (FOLD)

View Comments and Join the Discussion!